In addition, concomitant RASi treatment was associated with better survival in patients with metastatic renal cell carcinoma (RCC; gain in OS, 7 to 26 months) (137–140), metastatic CRC (gain in OS, ~11 months) (172), glioblastoma (175), and advanced hepatocellular carcinoma (HCC; gain in OS, ~5 months) (173) who received VEGF-targeted therapies. The gene discussed is MMP19; the disease is glioblastoma.